GlaxoSmithKline Appoints Directors to Board of New Consumer-Health Company Haleon

By Cecilia Butini

GlaxoSmithKline PLC said Tuesday that it has appointed six directors to the board of Haleon, the new company set to be formed through the demerger of Glaxo's consumer healthcare unit.

The British pharma giant said the appointments include two Glaxo nonexecutive directors and three new external members. Haleon's chief financial officer designate Tobias Hestler is expected to become executive director together with Chief Executive Officer Designate Brian McNamara, Glaxo said.

Mr. Hestler is exepected to be appointed as director prior to the company's demerger, which is expected in July 2022, while all the other appointments are to become effective starting from the demerger, Glaxo said.

Write to Cecilia Butini at [e-mail]

(END) Dow Jones Newswires

03-15-22 0632ET